Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical...

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• High-throughput genomic profiling has revolutionized cancer biology understanding.
• A shift from histology to molecular alterations guides targeted therapy and immunotherapy selection.
• Precision oncology tailors treatments to actionable molecular targets, irrespective of tumor origin.

Purpose of the Study:

• To review key trials supporting comprehensive genomic profiling in solid tumors.
• To examine evidence for tissue-agnostic drug approvals in cancer care.
• To highlight progress and remaining barriers in precision oncology implementation.

Main Methods:

• Review of clinical trials demonstrating the utility of comprehensive genomic profiling.
• Analysis of regulatory data supporting tissue-agnostic drug approvals.
• Discussion of challenges impacting precision oncology integration.

Main Results:

• Genomic profiling identifies molecular alterations predicting treatment response.
• Nine anticancer agents received tissue-agnostic approvals by 2025.
• Innovative clinical trial designs, including adaptive cohorts, facilitate drug assessment.

Conclusions:

• Precision oncology, driven by genomic profiling, has achieved significant regulatory milestones.
• Tumor heterogeneity and endpoint validation are key challenges for widespread adoption.
• Further integration of precision oncology into routine care requires addressing existing barriers.